Literature DB >> 7578115

Bisaldehyde allosteric effectors as molecular ratchets and probes.

T Boyiri1, M K Safo, R E Danso-Danquah, J Kister, C Poyart, D J Abraham.   

Abstract

Four new series of monoaldehyde bisacids and bisaldehyde bisacids with varying chain lengths have been synthesized and evaluated as allosteric effectors of hemoglobin. Molecular modeling, oxygen equilibrium, and crystallographic studies were combined for structure/function studies. Crystallographic analyses of the bisaldehydes reveal that Schiff base interaction occurred exclusively between Val 1 alpha and Lys 99 alpha of the opposite alpha chain even though the two terminal Val 1 alpha nitrogens are ideally spaced to also form cross-links. The reason for the observed mode of binding appears to be the influence of chain direction set by key substitutions on the bisaldehyde molecule. Even longer chain derivatives that could overcome the direction set by the key functional groups bind in the same manner. These studies support the general conclusion that long flexible molecules prefer to bind along cavity walls, like double-sided molecular sticky tape, rather than span large open spaces with few chances for interaction. The cross-linked bisaldehydes bind at the same site when incubated under both allosteric states and exhibit reduced cooperativity with a significant decrease in oxygen affinity. The chain length acts as a molecular ratchet and dictates the degree of allosteric effect observed. The tighter the cross-link, the greater the constraint on the tense- (T-) state and the stronger the allosteric effect that is produced. The monoaldehyde bisacids bind in the same fashion with Schiff base formation at Val 1 alpha while the acid that replaces the second aldehyde moiety forms a salt bridge with Lys 99 alpha of the opposite subunit. This class of molecules has weaker allosteric effector activity as would be expected with replacement of one covalent bond by a salt bridge. The importance of Lys 99 alpha on the allosteric equilibrium is confirmed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7578115     DOI: 10.1021/bi00046a008

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  7 in total

1.  Identification of a novel class of covalent modifiers of hemoglobin as potential antisickling agents.

Authors:  A M Omar; M A Mahran; M S Ghatge; N Chowdhury; F H A Bamane; M E El-Araby; O Abdulmalik; M K Safo
Journal:  Org Biomol Chem       Date:  2015-06-14       Impact factor: 3.876

2.  Crystallographic analysis of human hemoglobin elucidates the structural basis of the potent and dual antisickling activity of pyridyl derivatives of vanillin.

Authors:  Osheiza Abdulmalik; Mohini S Ghatge; Faik N Musayev; Apurvasena Parikh; Qiukan Chen; Jisheng Yang; Ijeoma Nnamani; Richmond Danso-Danquah; Dorothy N Eseonu; Toshio Asakura; Donald J Abraham; Jurgen Venitz; Martin K Safo
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2011-10-19

3.  Metal complexes as allosteric effectors of human hemoglobin: an NMR study of the interaction of the gadolinium(III) bis(m-boroxyphenylamide)diethylenetriaminepentaacetic acid complex with human oxygenated and deoxygenated hemoglobin.

Authors:  S Aime; G Digilio; M Fasano; S Paoletti; A Arnelli; P Ascenzi
Journal:  Biophys J       Date:  1999-05       Impact factor: 4.033

4.  Control of the allosteric equilibrium of hemoglobin by cross-linking agents.

Authors:  Michael C Marden; Marion Cabanes-Macheteau; Alexandru Babes; Laurent Kiger; Nathalie Griffon; Claude Poyart; Telih Boyiri; Martin K Safo; Donald J Abraham
Journal:  Protein Sci       Date:  2002-06       Impact factor: 6.725

Review 5.  Therapeutic strategies to alter the oxygen affinity of sickle hemoglobin.

Authors:  Martin K Safo; Gregory J Kato
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-21       Impact factor: 3.722

6.  Design, Synthesis, and Biological Evaluation of Ester and Ether Derivatives of Antisickling Agent 5-HMF for the Treatment of Sickle Cell Disease.

Authors:  Guoyan G Xu; Piyusha P Pagare; Mohini S Ghatge; Ronni P Safo; Aheema Gazi; Qiukan Chen; Tanya David; Alhumaidi B Alabbas; Faik N Musayev; Jürgen Venitz; Yan Zhang; Martin K Safo; Osheiza Abdulmalik
Journal:  Mol Pharm       Date:  2017-09-13       Impact factor: 4.939

7.  Molten globule of hemoglobin proceeds into aggregates and advanced glycated end products.

Authors:  Afshin Iram; Tauqeer Alam; Javed M Khan; Taqi A Khan; Rizwan H Khan; Aabgeena Naeem
Journal:  PLoS One       Date:  2013-08-26       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.